Phase 2 Study of MGL-3196 in Patients with Non-Alcoholic Steatohepatitis (NASH).
The NASH study is a multi-center, double-blind, randomized, placebo-controlled study in patients with Non-alcoholic Steatohepatitis (NASH). The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in patients with biopsy-proven NASH.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.